These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 25591543)
1. Peptide therapeutics: targeting the undruggable space. Tsomaia N Eur J Med Chem; 2015 Apr; 94():459-70. PubMed ID: 25591543 [TBL] [Abstract][Full Text] [Related]
2. Stabilized cyclic peptides as modulators of protein-protein interactions: promising strategies and biological evaluation. Cheng J; Zhou J; Kong L; Wang H; Zhang Y; Wang X; Liu G; Chu Q RSC Med Chem; 2023 Dec; 14(12):2496-2508. PubMed ID: 38107173 [TBL] [Abstract][Full Text] [Related]
3. Stapled Peptides Inhibitors: A New Window for Target Drug Discovery. Ali AM; Atmaj J; Van Oosterwijk N; Groves MR; Dömling A Comput Struct Biotechnol J; 2019; 17():263-281. PubMed ID: 30867891 [TBL] [Abstract][Full Text] [Related]
9. Targeting "Undruggable" Proteins: Design of Synthetic Cyclopeptides. Russo A; Aiello C; Grieco P; Marasco D Curr Med Chem; 2016; 23(8):748-62. PubMed ID: 26758797 [TBL] [Abstract][Full Text] [Related]
10. Design and Synthetic Strategies for Helical Peptides. Tu L; Wang D; Li Z Methods Mol Biol; 2019; 2001():107-131. PubMed ID: 31134570 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein-protein interactions using designed molecules. Wilson AJ Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049 [TBL] [Abstract][Full Text] [Related]
12. Modulators of 14-3-3 Protein-Protein Interactions. Stevers LM; Sijbesma E; Botta M; MacKintosh C; Obsil T; Landrieu I; Cau Y; Wilson AJ; Karawajczyk A; Eickhoff J; Davis J; Hann M; O'Mahony G; Doveston RG; Brunsveld L; Ottmann C J Med Chem; 2018 May; 61(9):3755-3778. PubMed ID: 28968506 [TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
14. Rational, computer-enabled peptide drug design: principles, methods, applications and future directions. Diller DJ; Swanson J; Bayden AS; Jarosinski M; Audie J Future Med Chem; 2015; 7(16):2173-93. PubMed ID: 26510691 [TBL] [Abstract][Full Text] [Related]
15. Cell-based peptide screening to access the undruggable target space. Hennemann H; Wirths S; Carl C Eur J Med Chem; 2015 Apr; 94():489-96. PubMed ID: 25458182 [TBL] [Abstract][Full Text] [Related]
17. Peptidomimetics Targeting Protein-Protein Interactions for Therapeutic Development. Zhang G; Andersen J; Gerona-Navarro G Protein Pept Lett; 2018; 25(12):1076-1089. PubMed ID: 30381055 [TBL] [Abstract][Full Text] [Related]
18. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Burke TR; Yao ZJ; Liu DG; Voigt J; Gao Y Biopolymers; 2001; 60(1):32-44. PubMed ID: 11376431 [TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Lee AC; Harris JL; Khanna KK; Hong JH Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31091705 [TBL] [Abstract][Full Text] [Related]
20. Towards intracellular delivery of peptides. Marzinzik AL; Vorherr TE Chimia (Aarau); 2013; 67(12-13):899-904. PubMed ID: 24594335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]